Boston, MANCT07755436Now EnrollingIRB Ready

Ovarian Cancer Clinical Trial in Boston, MA

Access cutting-edge ovarian cancer treatment through this phase 1 clinical trial at a research site in Boston. Study-provided care at no cost to qualified participants.

Sponsored by ArriVent BioPharma, Inc.

Quick Self-Assessment

See if you qualify for this Boston location

Preparing your pre-screening questions…

Expert Care in Boston

Access ovarian cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related ovarian cancer treatment provided free

Apply for This Boston Location

Check if you qualify for this ovarian cancer clinical trial in Boston, MA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Boston

    Convenient for MA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Boston site if eligible
  4. 4Begin participation

About This Ovarian Cancer Study in Boston

This is a Phase 1 study to assess safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of ARR-002 in advanced or metastatic ovarian or endometrial cancer.

Sponsor: ArriVent BioPharma, Inc.

Who Can Participate

Inclusion Criteria

Patients with histologically and cytologically confirmed advanced or metastatic ovarian, primary peritoneal, or fallopian tube cancer, and platinum resistant who have failed or intolerant to standard therapy, or without alternative standard therapy.
Patients must have at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1).
Tumor specimen available for testing, or agree to biopsy at baseline.
The score of Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Life expectancy ≥ 12 weeks.
Organ functions and coagulation function must meet the basic requirements.
Patients with childbearing potential must use effective contraception during the treatment and for 6 months after the last dose of treatment.

Exclusion Criteria

Prior treatment with auristatin-derived drugs s (eg, MMAE and monomethyl auristatin F \[MMAF\]).
Received antitumor therapy within 4 weeks prior to the first dose or 5 half-lives, whichever is shorter.
Infection of active hepatitis B, active hepatitis C, or HIV.
Symptomatic Central nervous system and/or meninges metastasis.
History of uncontrolled diabetes mellitus or diabetic neuropathy within 3 months before the first dose of study treatment.
Previous drug-induced interstitial lung disease (ILD) or active ILD.
Poorly controlled pleural, peritoneal, and pelvic effusion, or combined pericardial effusion.
History of recurrent gastrointestinal (GI) obstruction.
Patients with more than one cancer.
Any other diseases, pulmonary dysfunction, metabolic dysfunction, physical examination finding, or clinical laboratory finding
Grade ≥ 2 peripheral neuropathy
History of severe cardiovascular diseases.
Current use of anticoagulants or thrombolytic agents for therapeutic purposes.
Known allergic reactions to any component of ARR-002.
Prior treatment with MUC16- or NaPi2b-targeting agents.
Ocular conditions such as keratitis or corneal ulceration, monocularity, corneal transplantation, uncontrolled retinopathy, wet macular degeneration, uveitis, papilledema, or optic disc disorder.
Other situations that are not suitable to participate a clinical trial per investigator's judgement.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Boston?

Yes, this clinical trial (NCT07755436) has an active research site in Boston, MA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Ovarian Cancer Treatment Options in Boston, MA

If you're searching for ovarian cancer treatment options in Boston, MA, this clinical trial (NCT07755436) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Boston research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced ovarian cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all ovarian cancer clinical trials near you to find additional studies recruiting in your area.

More Ovarian Cancer Trials in Boston, MA

See all ovarian cancer clinical trials recruiting in Boston — not just this study.

Browse Ovarian Cancer Trials in Boston →

Browse More Trials by Condition

Ovarian Cancer TrialsAll Conditions →

Ready to Join in Boston?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Boston, MA